Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11239-020-02105-8 http://scihub22266oqcxt.onion/10.1007/s11239-020-02105-8 32246317!7124128!32246317     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 253.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Thromb+Thrombolysis 2021 ; 51 (4): 1107-1110 Nephropedia Template TP {{tp|p=32246317|t=2021. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 |pdf=|usr=}}{{32246317}} gab.com Text Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 JO: J Thromb Thrombolysis http://www.kidney.de/pget.php?&tw=1&pmid=32246317 #FOAvip Severe coronavirus disease 2019 (COVID-19) is commonly complicated with coagulopathy, the difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 has not been analyzed. Coagulation results and clinical features of consecutive patients with severe pneumonia induced by SARS-CoV2 (COVID group) and non-SARS-CoV2 (non-COVID group) in Tongji hospital were retrospectively analyzed and compared. Whether patients with elevated D-dimer could benefit from anticoagulant treatment was evaluated. There were 449 COVID patients and 104 non-COVID patients enrolled into the study. The 28-day mortality in COVID group was approximately twofold of mortality in non-COVID group (29.8% vs. 15.4%, P = 0.003), COVID group were older (65.1 +/- 12.0 vs. 58.4 +/- 18.0, years, P < 0.001) and with higher platelet count (215 +/- 100 vs. 188 +/- 98, x10(9)/L, P = 0.015), comparing to non-COVID group. The 28-day mortality of heparin users were lower than nonusers In COVID group with D-dimer > 3.0 mug/mL (32.8% vs. 52.4%, P = 0.017). Patients with severe pneumonia induced by SARS-CoV2 had higher platelet count than those induced by non-SARS-CoV2, and only the former with markedly elevated D-dimer may benefit from anticoagulant treatment. Twit Text FOAVip Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 ????J Thromb Thrombolysis http://www.kidney.de/pget.php?&tw=1&pmid=32246317 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32246317 #FOAvip English Wikipedia <ref>{{Cite pmid|32246317}}</ref> Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 #MMPMID32246317 Yin S; Huang M; Li D; Tang N J Thromb Thrombolysis 2021[May]; 51 (4): 1107-1110 PMID32246317show ga Severe coronavirus disease 2019 (COVID-19) is commonly complicated with coagulopathy, the difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 has not been analyzed. Coagulation results and clinical features of consecutive patients with severe pneumonia induced by SARS-CoV2 (COVID group) and non-SARS-CoV2 (non-COVID group) in Tongji hospital were retrospectively analyzed and compared. Whether patients with elevated D-dimer could benefit from anticoagulant treatment was evaluated. There were 449 COVID patients and 104 non-COVID patients enrolled into the study. The 28-day mortality in COVID group was approximately twofold of mortality in non-COVID group (29.8% vs. 15.4%, P = 0.003), COVID group were older (65.1 +/- 12.0 vs. 58.4 +/- 18.0, years, P < 0.001) and with higher platelet count (215 +/- 100 vs. 188 +/- 98, x10(9)/L, P = 0.015), comparing to non-COVID group. The 28-day mortality of heparin users were lower than nonusers In COVID group with D-dimer > 3.0 mug/mL (32.8% vs. 52.4%, P = 0.017). Patients with severe pneumonia induced by SARS-CoV2 had higher platelet count than those induced by non-SARS-CoV2, and only the former with markedly elevated D-dimer may benefit from anticoagulant treatment. |*COVID-19/blood/diagnosis/epidemiology/physiopathology[MESH] |*Pneumonia/blood/diagnosis/etiology[MESH] |*Sepsis/blood/diagnosis/etiology[MESH] |*Thrombophilia/diagnosis/etiology[MESH] |Age Factors[MESH] |Aged[MESH] |Blood Coagulation Tests/methods[MESH] |China/epidemiology[MESH] |Diagnosis, Differential[MESH] |Female[MESH] |Fibrin Fibrinogen Degradation Products/analysis[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Organ Dysfunction Scores[MESH] |Platelet Count/*methods[MESH] |Retrospective Studies[MESH] |Risk Factors[MESH]Difference of coagulation features between severe pneumonia induced by(epmc).pdf DeepDyve Pubget Overpricing